Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma

Q1 Medicine

CNS Oncology Pub Date : 2019-11-29 DOI:10.2217/cns-2019-0016

Meetakshi Gupta, T. Gupta, N. Purandare, V. Rangarajan, A. Puranik, A. Moiyadi, P. Shetty, S. Epari, A. Sahay, A. Mahajan, A. Janu, B. Bagal, H. Menon, S. Kannan, R. Krishnatry, G. Sastri, R. Jalali

{"title":"Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma","authors":"Meetakshi Gupta, T. Gupta, N. Purandare, V. Rangarajan, A. Puranik, A. Moiyadi, P. Shetty, S. Epari, A. Sahay, A. Mahajan, A. Janu, B. Bagal, H. Menon, S. Kannan, R. Krishnatry, G. Sastri, R. Jalali","doi":"10.2217/cns-2019-0016","DOIUrl":null,"url":null,"abstract":"Aim: To prospectively assess the clinical utility of pretreatment flouro-deoxy-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in patients with primary central nervous system (CNS) lymphoma (PCNSL). Materials & methods: Patients with suspected/proven PCNSL underwent baseline whole-body 18F-FDG-PET/CT. Maximum standardized uptake value and tumor/normal tissue ratios were compared between CNS lymphoma and other histological diagnoses. Results: The mean maximum standardized uptake value (27.5 vs 18.2; p = 0.001) and mean tumor/normal tissue ratio (2.34 vs 1.53; p < 0.001) of CNS lymphoma was significantly higher than other histologic diagnoses. Five of 50 (10%) patients with biopsy-proven CNS lymphomas had pathologically increased FDG-uptake at extraneuraxial sites uncovering systemic lymphoma. Conclusion: Pretreatment whole-body 18F-FDG-PET/CT provides valuable complementary information in the diagnostic and staging evaluation of patients with PCNSL to guide therapeutic decision-making.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"23 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2019-0016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 14

Abstract

Aim: To prospectively assess the clinical utility of pretreatment flouro-deoxy-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in patients with primary central nervous system (CNS) lymphoma (PCNSL). Materials & methods: Patients with suspected/proven PCNSL underwent baseline whole-body 18F-FDG-PET/CT. Maximum standardized uptake value and tumor/normal tissue ratios were compared between CNS lymphoma and other histological diagnoses. Results: The mean maximum standardized uptake value (27.5 vs 18.2; p = 0.001) and mean tumor/normal tissue ratio (2.34 vs 1.53; p < 0.001) of CNS lymphoma was significantly higher than other histologic diagnoses. Five of 50 (10%) patients with biopsy-proven CNS lymphomas had pathologically increased FDG-uptake at extraneuraxial sites uncovering systemic lymphoma. Conclusion: Pretreatment whole-body 18F-FDG-PET/CT provides valuable complementary information in the diagnostic and staging evaluation of patients with PCNSL to guide therapeutic decision-making.

查看原文本刊更多论文

氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在原发性中枢神经系统淋巴瘤患者的诊断和分期评估中的应用

目的:前瞻性评价预处理氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(18F-FDG-PET/CT)在原发性中枢神经系统淋巴瘤(PCNSL)患者中的临床应用价值。材料与方法:疑似/确诊PCNSL患者行基线全身18F-FDG-PET/CT检查。比较中枢神经系统淋巴瘤和其他组织学诊断的最大标准化摄取值和肿瘤/正常组织比率。结果:平均最大标准化摄取值(27.5 vs 18.2;P = 0.001)，平均肿瘤/正常组织比值(2.34 vs 1.53;p < 0.001)的发病率明显高于其他病理诊断。50例活检证实的中枢神经系统淋巴瘤患者中有5例(10%)在病理上在轴外部位fdg摄取增加，发现全身性淋巴瘤。结论:预处理全身18F-FDG-PET/CT为PCNSL患者的诊断和分期评估提供了有价值的补充信息，指导治疗决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊